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Abstract. Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by the presence in the brain of extracellular
amyloid-protein (A) and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein. The N-Methyl-
D-aspartate receptors (NMDAR), ionotropic glutamate receptor, are essential for processes like learning and memory. An
excessive activation of NMDARs has been associated with neuronal loss. The discovery of extrasynaptic NMDARs provided
a rational and physiological explanation between physiological and excitotoxic actions of glutamate. Memantine (MEM), an
antagonist of extrasynaptic NMDAR, is currently used for the treatment of AD jointly with acetylcholinesterase inhibitors. It
has been demonstrated that MEM preferentially prevents the excessive continuous extrasynaptic NMDAR disease activation
and therefore prevents neuronal cell death induced by excitotoxicity without disrupting physiological synaptic activity. The
problem is that MEM has shown no clear positive effects in clinical applications while, in preclinical stages, had very promising
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results. The data in preclinical studies suggests that MEM has a positive impact on improving AD brain neuropathology, as
well as in preventing A production, aggregation, or downstream neurotoxic consequences, in part through the blockade of
extrasynaptic NMDAR. Thus, the focus of this review is primarily to discuss the efficacy of MEM in preclinical models of
AD, consider possible combinations of this drug with others, and then evaluate possible reasons for its lack of efficacy in
clinical trials. Finally, applications in other pathologies are also considered.
Keywords: Alzheimer’s disease, amyloid -protein, extrasynaptic N-Methyl-D-aspartate receptor, memantine, tau protein
INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative
pathology of severe prognosis, currently incurable,
and highly prevalent in aged people [1]. The first
description of the disease was carried out in 1906
by a German psychiatrist and neurologist, Alois
Alzheimer, when exploring the brain tissue of a
patient, Auguste Deter, who had died from a men-
tal illness unknown at that time [2, 3]. Today, it is the
cause of 50–70% of dementia cases and, according to
the Alzheimer’s Association, 13% of people over 65
in developed countries suffer from AD, where it is the
fifth cause of death in patients of this age group [1, 4].
If unchecked, global incidence will quadruple to 114
million by 2050 according to population growth pro-
jections by the World Health Organization (WHO)
[1]. This would imply unsustainable economic bur-
dens for all health systems, in addition to its social
impact.
AD can be classified according to the age at which
it begins to manifest, that is, if it has an early onset,
developing before the age of 65 (3–5% prevalence),
or if it occurs after the 65 years of age (95–97%
prevalence) [1]. Additionally, the pathology may be
of hereditary or sporadic origin, the latter being the
most common (98% prevalence). Pathogenesis of
late onset AD is very complex. Other than aging,
which is the main factor involved in the devel-
opment of the disease, it may be associated with
dietary and environmental factors, including long
term consumption of high caloric diets and sedentary
lifestyles [1, 4]. Overall, it is the interaction of multi-
ple genetic and environmental risk factors that lead to
AD, together with the disruption of epigenetic mech-
anisms controlling gene dynamics and expression
[4–10].
The main symptom of AD is memory loss, which
is correlated with a decline of neuron population
in the hippocampus, a brain area critical for learn-
ing and memory [9, 10]. In addition, the entorhinal
cortex, area of interface between the hippocam-
pus and the neocortex for the formation of spatial
memory, becomes affected by this pathology. It has
been reported that the hippocampus is especially
vulnerable to damage at early stages in AD and
approximately 25–70% of neurons are lost in this area
[9, 10].
In the familial form of the disease, A peptide for-
mation, in particular its longer form A42, is triggered
by mutations in the amyloid- protein precursor
(APP, chromosome 21), presenilin 1 (PS1, chro-
mosome 14), and presenilin 2 (PS2, chromosome 1)
genes. Also, the APOE gene, another risk factor for
the development of AD, has been characterized (2,
3, and 4) [1, 4, 10–12]. It has been described that
the 2 allele has a protective role in AD, while 4
has the opposite effect, since it favors the appearance
of AD. Although late onset AD appears with higher
incidence when the 4 isoform is affected, the exact
mechanism of how APOE triggers the formation of
amyloid deposits is unknown [11, 12]. The lack of
knowledge on the actual mechanisms that trigger the
appearance of this multifactorial disease is the exact
cause that leads us to having no cure for its treatment
[11–13].
Memantine (MEM), a low-affinity voltage-
dependent uncompetitive antagonist of NMDA
receptors (NMDAR), is currently being prescribed
for the treatment of AD jointly with acetylcholines-
terase inhibitors such as galantamine, donepezil, and
rivastigmine [11, 14–17]. Since it is a low-affinity
antagonist, it blocks the NMDAR but it is rapidly dis-
placed from it, avoiding prolonged receptor blockade
and the associated negative side effects on learn-
ing and memory that have been observed in high
affinity NMDAR antagonists (dissociative anesthet-
ics, ketamine, and MK-801). MEM also has a suitable
safety and tolerability limits showing a good thera-
peutic margin. Another advantage of MEM is that it
only interacts with the channel when it is pathologi-
cally activated under an excessive glutamate concen-
tration in the synaptic cleft, as is the case with AD.
In addition, preclinical data has reported that MEM
could block other receptors, such as nicotinic, acetyl-
choline, serotonin, and sigma-1 receptors [17–19].
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Historically, MEM was first synthesized by the Eli
Lilly laboratories as a compound for the treatment
of diabetes, but it was ineffective [14, 15, 20–24].
In 1972, Merz Pharma applied for a German patent
presenting MEM as a potential treatment for various
neurological diseases [14, 15]. In the early 1990s, the
company initiated the research of efficacy and safety
of MEM in nursing patients with severe dementia.
In 1999, Forest Laboratories acquired the license for
using MEM and initiated a series of clinical studies
in both moderate to severe AD. MEM was approved
for the treatment of moderately severe to severe AD
in 2002 by the European Agency for the Evalua-
tion of Medical Products (EMEA). Complementarily,
the efficacy of MEM was evaluated as monother-
apy or combined with acetylcholinesterase inhibitors
[24]. The dosing regimen of 10 mg bid was based on
previous clinical trial experience.
So far though, the biggest problem that is encoun-
tered with MEM and any other approved treatment
for AD, is that they do not slow down the progres-
sion of the disease, but only have symptomatic effect
[26]. That is why current efforts in AD therapy are
focusing on the research and development of new
molecules that can modify the course of AD pro-
gression [27, 28]. Among the major drugs that are
in development, we observe some already in Phase
III: inhibitors of the -site amyloid precursor protein
cleaving enzyme (BACE) (CNP520, LY3314814,
and verubecestat) and antibodies against the A
peptide (aducanumab, solanezumab, crenezumab,
gantenerumab, and BAN2401) [22, 27].
Because MEM has already been approved and used
for AD and data points out possible combinations
with other drugs in the future, in this review we will
evaluate the different reported results on MEM at the
preclinical levels on different stages of AD progres-
sion. Also, the different mechanisms involved in the
beneficial effects of MEM in the preclinical levels
will be discussed. Finally, the lack of MEM effi-
cacy on clinical AD and the potential use of MEM
in neurological diseases will be discussed.
SYNAPTIC AND EXTRASYNAPTIC
METHYL-D-ASPARTATE RECEPTORS
(NMDAR)
The NMDAR are cationic channels controlled
by the excitatory neurotransmitter glutamate, which
plays an essential role in the physiological process
of learning and memory in the central nervous
system (CNS) [14, 15, 20–26]. The NMDAR can
be classified in different subunits called NR1 and
NR2A–D [14, 15, 21–25]. In AD, an excessive
release of glutamate and, an increasing concentra-
tion of soluble A, which has been hypothesized to
increase the activity of the receptor [23] and lead
to an excessive Ca2+ flux within the cell, as well as
free radical generation. The intense influx of Ca2+
impairs mitochondrial function activating transition
pores in the inner mitochondrial membrane, which
causes the release of cytochrome c, the posterior
depletion of ATP, and simultaneous formation of
reactive oxygen species (ROS) [23]. These cytotoxic
events are associated with synaptic dysfunction and
tau phosphorylation. [23].
Depending on the localization of the NMDAR in
the neuron, they have been classified in two groups
[20, 22]:
• The synaptic NMDARs have both presynaptic
and postsynaptic locations on neurons [29]. The
presynaptic receptors play a role in synaptic
transmission and plasticity of neuronal net-
works, while postsynaptic only have a role in
the control of plasticity [28–31]. Both types are
involved in the activation of neuronal protective
and survival genes [29, 30].
• Extrasynaptic NMDARs are located on den-
drites and require high glutamate concentrations
in order to be activated [31]. These NMDARs
are characterized by favoring the NR2B subunit
which, when excessively stimulated, contribute
to neurotoxicity and the control of neuronal cell
death. Moreover, extrasynaptic NMDARs are
involved in the regulation of A production and
thus in the neuropathology of AD [29–32]. They
are the main target of MEM.
According to this information, MEM is the only
approved antagonist against extrasynaptic NMDARs
and the treatment of AD. Its selective action without
affecting the physiological NMDAR synaptic activity
allows neuroprotective effects brain [20–23].
CLINICAL PATHOPHYSIOLOGY OF
ALZHEIMER’S DISEASE
Initial postmortem brain histopathological exam-
ination of AD patients led to the characterization
of the two classical hallmarks of the disease: senile
plaques and neurofibrillary tangles (NFT) [1, 4, 6, 10,
21, 26, 32]. Senile plaques are extracellular deposits,
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diffuse or compact, that can be found in the brain of
patients with AD, and that are composed of insoluble
A peptides of 39 to 43 amino acids [21]. Diffuse
plaques are A deposits that do not visibly alter
the surrounding neuropil, or induce glial response
around them, and are considered relatively benign,
since they have been found in cerebral cortex sam-
ples of elderly subjects that presented no cognitive
impairment [4, 10]. In contrast, compact plaques are
often surrounded by dystrophic neurites, reactive
astrocytes, and activated microglia, rendering them
more neurotoxic. In addition, senile plaques may also
contain mucopolysaccharides, 1-antiquimiotripsin,
immunoglobulins, complement factors, fibrinogen,
APOE, cholesterol, presenilins, cytokines (IL-1,
IL-6, TGF-, TNF-), intercellular adhesion
molecule 1 (ICAM-1), clusterine, -synuclein, and
inorganic elements [10].
The original hypothesis on the origin of AD
was focused on alterations on the usual activity of
the amyloid cascade [33–35]. This hypothesis is
based on the following process: first, APP is pro-
cessed by the amyloidogenic route, a pathway in
which - and -secretases cleave APP, causing an
excessive production of A peptide and/or a defect
of its elimination [33–39]. This process causes its
oligomerization and accumulation in the form of
senile plaques in the brain cortex, hippocampus, and
other brain areas. To better understand the mecha-
nism, it will be explained further:
Initially, the A peptide is generated from the
catabolism of APP, a plasma membrane protein
with a single domain found in different cell types,
including neurons, astrocytes, oligodendrocytes, and
glial cells. It is encoded by a gene located on chro-
mosome 21, which when expressed gives rise to 8
isoforms, of which APP695 is the most abundant
in the brain [38]. This protein is cleaved by -,
, and -secretase enzymes and a complex of pro-
teins containing PS1. In a physiological situation,
following the non-amyloidogenic pathway, APP is
catabolized by -secretases, producing a sAPP
fragment that remains in the extracellular space, and a
carboxyl-terminal fragment of 83 amino acids (C83),
that is anchored on the plasma membrane [35–39].
sAPP regulates neuronal excitability, improves
synaptic plasticity, learning, and memory, and also
increases the resistance of neurons to oxidative
and metabolic stress. However, in neuropathological
situations, APP is metabolized by the amyloido-
genic pathway in which the  amyloid cleaving
enzyme 1 (BACE 1;-secretase) breaks APP by the
N-terminal end while -secretases cleave the
C-terminal end, obtaining fragments A40 and A42
that remain in the extracellular space and cause neg-
ative effects.
In addition, it is believed that in non-pathological
conditions the A peptide is produced continuously
and that its aggregation and deposition in AD is the
consequence of its rise on concentration that makes
it precipitate [38, 39]. In physiological conditions,
the amyloid protein is produced in normal amounts
in its soluble form due to cleavage of APP by
the -secretase enzyme, and is eliminated by the
action of degrading enzymes such as neprilysin, the
insulin-degrading enzyme, and the angiotensin con-
verting enzyme I. Yet, when sporadic AD occurs,
the balance between the non-amyloidogenic and the
amyloidogenic pathway becomes altered and, there
is an excessive production of A, resulting from the
cleavage of APP by the - and -secretase enzymes
and a lower degradation of A due to a lower activ-
ity of the degrading enzymes previously mentioned,
thus causing an imbalance between the production
and elimination of A [33–40].
However, even though there is a demonstrated role
of senile plaques on this excitotoxicity that leads to
AD, these events do not always correlate, and soluble
A might the one responsible for synaptic loss and
the symptomatology of AD [35–40]. In addition, over
the years it has been demonstrated that high A levels
in the brain lead to NFT formation, cell loss, vas-
cular damage, and dementia [10, 40]. The presence
of NFTs, which are intracellular deposits of helical
paired filaments composed of abnormally hyperphos-
phorylated tau protein, is well characterized in AD
brains [36–40]. The physiological function of tau is
related to the stabilization of the microtubule poly-
merization and proper axon functionality and, to a
lesser extent, the structuration of dendrites and den-
dritic spines in neurons when interacting with tubulin
[41, 42]. Tau regulates axonal transport of proteins,
vesicles, and organelles. In AD, tau hyperphospho-
rylation causes abnormal associations with tubulin,
favoring cytoskeleton alterations [42]. This aberrant
association causes for the filaments of tau to become
insoluble and precipitate as NFTs in synapses, axonal
structures, and neuronal bodies, causing neuronal
death by apoptosis [40–42].
In the end, all these cascade mechanisms, along
with the previously described alterations issued by
the NMDAR interacting with the A, add up to
the appearance of dementia due to neuronal activity
decline without clear evidence on the real culprit.
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EFFECTS OF MEMANTINE ON THE
AMYLOID CASCADE
Due to the negative consequences derived of the
presence of compact senile plaques in the brain, they
have become one of the main targets when trying
to design appropriate treatments for AD. Several
preclinical studies have reported that MEM leads
to a reduction in A brain levels or reduces amy-
loid plaque burden in preclinical mice models of
AD, which contributes to memory improvement [43].
Specifically, 3-month-old APP/PS1 mice treated with
MEM (10 mg/kg/day; i.p.) for a period of 4 months
showed a significant decrease in amyloid plaque bur-
den in the brain (cortex and hippocampus) [44].
Furthermore, MEM was effective improving short-
term memory deficits in APP/PS1 mice, based in
exploratory behavior results using the novel-object
recognition test [44]. Moreover, Liu and colleagues
treated 12-month-old APP/PS1 mice with MEM
(5 mg/kg body weight) via intragastric administra-
tion and, they demonstrated that MEM treatment
improved memory and learning impairment and sig-
nificantly decreased A deposits in mice brains [45].
Parsons and colleagues demonstrated that after a
chronic in vitro treatment, MEM was accumulated in
the phospholipid membrane and could have modula-
tory effects on membrane fluidity [46]. This effect
could also modulate activity of membrane-bound
enzymes, such as APP and BACE-1 and probably
explain the anti-A effects of MEM.
Recently, Ito and colleagues reported that MEM
reduces the brain levels of A in Tg2576 mice that
have plaques and the levels of insoluble endoge-
nous A in aged F344 rat brains. Authors suggest
a new mechanism involved through the modulation
of APP trafficking and stabilization of APP on the
cell surface, which favors a reduction in A produc-
tion [47].
Therefore, after evaluating the results, some
authors have suggested that MEM effects on
NMDAR do not only associate the neuroprotec-
tive effect observed with its administration. Some
authors reported that there are additional mecha-
nisms in MEM neuroprotection like nerve growth
factor upregulation that activates the tropomyosin
receptor kinase A (Trk A) signaling, which even-
tually inhibits p75 neurotrophin receptor (p75NTR),
molecules implicated in neuronal plasticity [48]. In
addition, it causes increases on brain levels of the
brain-derived neurotrophic factor (BDNF) and Trk B
and muscarinic receptors [48]. Furthermore, MEM
attenuated A42-induced loss of cholinergic neu-
rons and microglia activation in the neocortex [49].
Interestingly, no beneficial effects were observed
after subchronic MEM treatments in 5XFAD mice
at 12–15 months of age [50]. Authors suggest that
MEM cannot protect from memory loss at advanced
disease stages due to high levels of A in the tissue.
Thus, although in preclinical models it has been
demonstrated that MEM memory improvement is
due to reduction of cerebral A levels and amyloid
burden, in this study it was suggested that MEM
improves hippocampal memory in young 5XFAD
mice by blocking extrasynaptic NMDARs without
affecting A levels. In addition, authors suggest that a
suitable AD treatment might be the co-administration
of an A-lowering therapy (-secretase inhibitors to
reduce A production) together with MEM (which
prevents synaptic toxicity of oligomeric A). These
Fig. 1. Historical perspective of Alzheimer’s disease. Amyloid cascade hypothesis was suggested in 1992. The role of excitotoxicity in AD
was suggested about 1997.
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Fig. 2. Memantine improve preclinical Alzheimer’s disease neuropathology though increasing BDNF levels, synapses, improving cognition,
decreasing neuroinflammation, BACE-1 blockade, and NMDA receptor inhibition.
Fig. 3. We hypothesized that the potential beneficial metabolic effects of MEM are mediated by the inhibition of peripheral (pancreatic)
NMDAR and the blockade of hypothalamic A1-42 levels. Therefore, AD could be a cognitive disorder associated to metabolic alterations
both in central (insulin receptors) and peripheral areas.
data in experimental models of AD with old 5XFAD
mice could probably explain why the clinical effi-
cacy of the monotherapeutic MEM approach is lost
in moderate to severe memory deficits in advanced
AD patients [37]. Likewise, De Felice group reported
the importance of A oligomer species in the mech-
anisms of pathogenesis of AD [51]. A oligomers
self-assemble to form multiple types of soluble
oligomers (AOs) including low molecular weight
(dimers, trimers, tetramers) and high molecular-
weight species ranging in mass from 54 to 150 KDa.
AOs are involved in the process of synaptic and
cognitive dysfunction in AD. In this study, authors
demonstrate that MEM was effective only on high
molecular-weight oligomers and concluded that the
limited clinical efficacy of MEM in AD could be
explained by this selectivity [51].
MEMANTINE INHIBITS
NEUROFIBRILLARY TANGLES
FORMATION AT PRECLINICAL LEVEL
It is well known that the process of tau hyper-
phosphorylation at multiple sites is controlled by
several serine/threonine kinases, including pro-
tein kinase A, c-Jun N-terminal Kinase (JNK),
Fyn kinase, 5’ adenosine monophosphate-activated
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protein kinase, glycogen synthase kinase 3
(GSK3), cyclin dependent kinase 5 (CDK5), micro-
tubule affinity regulating kinase, extracellular signal
regulated kinase 2, and Ca2 + /calmodulin-dependent
protein kinase II [52–57]. Thus, these kinases
increase the phosphorylation of tau and prevent
the ability of tau to promote microtubule assembly
and facilitate the polymerization of tau into paired
helical filament. The process of tau dephosphoryla-
tion in the brain is mainly regulated by the protein
phosphatase 2A.
Kamat and colleagues suggest that NMDAR
activation increases tau phosphorylation by a com-
bined process with oxidative stress. It activates the
CDK5 signaling pathway and stress-activated protein
kinases JNK/SAPK [58]. So, considering the ele-
ments we have already reviewed, the interaction of the
A peptide with the NMDAR favors an increase on
the concentration of intracellular Ca2+, which acti-
vates the CDK5 and SAPK/JNK that, in the end,
induce the hyperphosphorylation of tau protein.
Briefly, the mechanisms through which kinases
named above phosphorylate tau are described below.
CDK5-mediated tau phosphorylation
CDK5 belongs to the family of cyclin-dependent
Ser/Thr protein kinases (CDKs) and carries out the
activation and maintenance of numerous physiologi-
cal functions in the nervous system, including neurite
and axon growth [43]. The accumulation of A, as
well as oxidative stress and other mechanisms of exci-
totoxicity, can lead to canonical activation of calpain
through significant increases of Ca2+ in the cyto-
plasm after NMDAR activation [59]. When active,
calpain binds to CDK5 and favors its overactivation
and phosphorylation of proteins such as tau. Zimmer
and colleagues demonstrated that MEM prevented
hippocampal activation of CDK5 after brain okadaic
acid administration, which induces AD-like pheno-
type in rats [60].
GSK3β-mediated phosphorylation
Increasingly, AD is being linked to insulin resis-
tance [61]. Insulin molecules bind to their receptors
and activates them. The phosphoinositol 3 kinase
binds to this receptor by the SH2 domain and
converts the phosphatidylinositol-4,5-bisphosphate
into phosphatidylinositol-3,4,5-triphosphate, which
binds to the protein kinase B (AKT), a Ser/Thr
kinase. AKT is then phosphorylated and activated
by phosphoinositide-dependent kinase, which in turn
phosphorylates GSK3 [62]. The Ser/Thr protein
kinase GSK-3 contains two distinct forms: an
active form (Ser9 phosphorylated), which is the most
abundant in the nucleus, mitochondria, and lipid
membrane, and a cytosolic inactive form. AKT inac-
tivates GSK-3 by phosphorylating it, activating
anti-apoptotic mechanisms and antioxidant defenses
[63–65]. When AD causes insulin resistance, the
insulin receptor is not activated, so GSK3 would be
on its active form and could phosphorylate the tau and
cause neuronal death [61]. De Sarno and colleagues,
as well as Martinez-Coria and colleagues, reported
that MEM was able to inhibit GSK3 activation in
different experimental models [66, 67]. Therefore,
the modulation of GSK3 phosphorylation by MEM
may contributes to the therapeutic actions of this
drug used in the treatment of AD. These results were
more significant since MEM improved additional AD
hallmarks such as cognitive dysfunction, probably
also associated in part, with inhibition of tau hyper-
phosphorylation, which governs the major synaptic
dysfunction by forming tangles.
RESULTS OF ALZHEIMER’S DISEASE
APOE E4 CARRIER PATIENTS TREATED
WITH MEMANTINE
Although APOE 4 is a well characterized AD risk
factor, the role of APOE 4 as a modulator of disease
progression, and its pharmacogenetic effects on AD
therapies, are a matter of controversy [67].
One the one hand, for example, Han and col-
leagues compared the efficacy of rivastigmine patch
monotherapy or MEM plus rivastigmine patch in
patients with mild to moderately severe AD, present-
ing different polymorphisms of the APOE genotype
[68]. The study demonstrated that the association
MEM plus the rivastigmine transdermal patch ther-
apy had beneficial effects on the activities of daily
living (ADL) in moderately severe AD patients with
the APOE 4 allele [68, 69]. On the other hand,
Wroolie and colleagues evaluated the effects of MEM
on cognition in women with risk of AD and included
a control group for the genetic risk factor for AD
the APOE 4 in a prospective open-label 6-month
long pilot medication trial [70]. The results of this
study were negative and authors concluded that
this study does not support the potential usefulness
of MEM in the prevention of cognitive decline or
dementia [70].
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CONTROL OF THE DEVELOPMENT OF
INFLAMMATORY RESPONSES AND
OXIDATIVE STRESS BY MEMANTINE
In AD, it has been demonstrated that neuroin-
flammatory responses derived of glial activation
play a prominent role in the induction of oxidative
stress [71]. Thus, several studies have reported a
decreased risk of AD in patients taking non-steroidal
anti-inflammatory drugs (NSAID) [72]. Furthermore,
long-term use of NSAIDs appears to be effective in
reducing the incidence of AD [72]. In addition, the
vast majority of studies of MEM focus mainly on
its effects on neurons, while MEM interacts with
other cell types in the CNS [14, 15, 73]. In pre-
clinical models of this disease, neuroinflammatory
markers like microglia and astroglia reactivity have
been observed, yielding interesting results and show-
ing decreases in neuroinflammatory biomarkers after
MEM treatments.
Usually, in the brains of AD patients, microglial
cells are highly reactive, mobile, and located close
to amyloidal plaques. It has been hypothesized that
this cell type could have different roles in the com-
plex mechanisms that lead to the appearance of
neuropathological conditions [71]. Firstly, microglia
would have a protective role in the initial stages
of the disease, phagocyting A peptides. Secondly,
when the disease progresses, microglia would be one
of the responsible cell types in the development of
proinflammatory and neurotoxic responses due to the
release of molecules like cytokines [73]. The increase
of substances such as TNF and IL-1, jointly with
mediators such as nitric oxide or ROS, produced by
glial cells, favor an exacerbation of AD pathology
[71, 73, 74]. In addition, IL-1 appears to induce
APP production, increasing A brain levels, which
in turn would induce further interleukin production
by microglia. Thus, a positive feedback cycle would
be created. Therefore, although clinical trials do not
support the efficacy of NSAIDs, this group of drugs
or others with similar properties may have a thera-
peutic effect on AD [71]. Interestingly, it has been
reported that MEM has an anti-inflammatory action
on microglial cells through the inhibition of inwardly
rectifying K+ (Kir) channels [75].
An excellent study performed by Kaindl and col-
leagues reported the existence of microglial NMDAR
that when overactivated, would cause the develop-
ment of inflammatory responses and trigger brain
damage processes [76]. They suggest a key role of
microglial NMDARs in the secretion of neurotoxic
factors such as interleukins, TNF, ROS, and nitric
oxide. In addition, these authors hypothesize that in
the brain a neuron-glia positive feedback cycle is gen-
erated through glutamate release by neurons favoring
glial activation [76]. Thus, MEM, through the block-
ade of glial NMDAR, could exert neuroprotective
effects through anti-inflammatory mechanisms. This
point was further demonstrated by De Felice and
colleagues who reported that neuronal hippocampal
cultures treated with A oligomers favor an increase
in ROS formation through NMDAR activation [77].
They demonstrated the neuroprotective effects of
MEM showing results of protection against synapsis
loss.
Wu and colleagues reported that MEM increases
the release of glial cell-derived neurotrophic fac-
tor (GDNF) from astroglia, which may account
for its neuron survival-enhancing effect in primary
neuron–glia cultures [78]. Caumont and colleagues
also demonstrated on an in vitro study, that MEM
administration in a C6 glioma cell line increased
GDNF production, suggesting that MEM neuropro-
tective effects in brain neurons could be also due to
the release of neurotrophic factors from glial cells
[79]. Interestingly, neurotrophic effects of MEM were
significantly inhibited when a neutralizing GDNF
antibody was added to the cell cultures. Willard
and colleagues reported that MEM also attenuated
cytotoxic effects [80]. Specifically, MEM allevi-
ated inflammatory processes mediated by chronical
lipopolysaccharide administration into the basal fore-
brain of mice [81–83]. Consequently, it has been
suggested that a chronical combined administration
of MEM and NSAIDs could be a suitable strategy to
delay the onset or slow the progression of AD [83].
ALTERNATIVE APPLICATIONS OF
MEMANTINE IN OTHER PATHOLOGIES
RELATED TO THE MODULATION OF
BRAIN BDNF LEVELS
Meisner and colleagues were the first group to
report new significant pharmacological actions of
MEM unrelated with NMDAR blockade, the mod-
ification brain protein expression of BDNF [48].
In fact, they demonstrated that when administering
MEM to rhesus monkeys (Macaca mulatta) infected
with immunodeficiency virus (HIV), brain protein
levels of BDNF increase. Likewise, studies with
other NMDAR antagonists suggest that they can
modulate the levels of brain BDNF, pointing to a
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potential role of glutamate in the activity of this neu-
rotrophic factor [84]. Interestingly, several preclinical
studies have evidenced that in addition to its appli-
cations for AD, MEM displays antidepressant-like
effects in rodents subjected to experimental models
of depression [85]. In addition, the co-administration
in rodents with MEM and ketamine or MEM with
sertraline, increased BDNF protein levels in the
hippocampus of rats [86, 87]. In addition, using
other NMDAR antagonists, the association of fluox-
etine and amantadine also induced robust significant
increases of both BDNF protein and mRNA gene
expression in rodent brain [88]. An additional benefit
of the use of MEM that is not related to neurode-
generative diseases, is its therapeutic application in
the treatment of alcoholism. Specifically, it has been
hypothesized that the results would be the conse-
quence of the effects of MEM on BDNF and its role
in alcohol consumption [89]. Finally, since BDNF is
an inductor of the expression of markers for synapto-
genesis, as well as, is a regenerator of on synaptic
sites, Zhu and colleagues evaluated the effects of
MEM in preclinical models of Parkinson’s disease
induced by the administration of 1-methyl-4-phenyl-
1.2.3.6-tetrahydropyridine [90]. This models causes
for reductions of BDNF levels in the hippocampus,
usually being associated with reductions to long-
term potentiation. MEM treatment increased BDNF
expression and restored long-term potentiation
[90].
To summarize, all this data related to the
effects of MEM on BDNF opens new possibili-
ties on its possible applications for the treatment of
neurological-neurodegenerative diseases [91].
MEMANTINE TREATMENT HAS EFFECTS
BOTH IN BRAIN AND PERIPHERAL
METABOLIC BIOMARKERS RELATED
TO DIABETES AND INSULIN METABOLISM
Some studies have reported a close association
between late onset AD and type 2 diabetes, a dis-
order usually related with obesity, going so far as
demonstrating already severe impairments of glucose
metabolism in mild cases of AD [8, 13, 92–97]. Thus,
lifestyle, particularly in terms of physical activity and
diet, has important effects on health and cognitive
processes, during aging in humans [13]. However, the
interaction between obesity, aging, and AD is com-
plex, with some evidence pointing out to the negative
effects of obesity in early adulthood. Specifically,
some authors have demonstrated that the develop-
ment of obesity in those ages substantially increases
the risk of developing AD [93–96]. This point is very
interesting, since recent data suggests that AD should
be considered as an affection of the entire organism
and not only the brain, possibly having a partial origin
in peripheral metabolic alterations [94, 95].
Following the same line of thought, Marquard and
colleagues reported the presence of NMDARs in pan-
creatic -cells [93]. These authors demonstrated that
dextromethorphan (NMDARs antagonist) regulated
insulin secretion in pancreas [93, 94]. Dextromethor-
phan blocked NMDARs, preventing the activation
of K+ channels, reducing its efflux from the cell,
and prolonging the time the depolarized state of
-cells [93, 97]. Consequently, intracellular Ca2+
concentration increased leading to insulin release and
improvement of the diabetic state. However, even
though the results are very interesting, it must be
taken into account that strong NMDAR antagonists
have considerable cognitive side effects and MEM,
being a partial antagonist, might be a better choice
for long-term drug usage [97–99].
Considering these results, the use of MEM could
not only alleviate the symptomatology in the cen-
tral nervous system but also in peripheral tissues.
In our research group, we have studied the effects
of MEM on APPswe/PS1dE9 mice fed with a high-
fat diet (unpublished results). The animals were fed
with a high-fat diet until 7-8 months of age and
they were treated with MEM-supplemented water
(30 mg/kg) during the last 12 weeks. In this study,
MEM improved peripheral metabolic parameters like
insulin resistance. Moreover, MEM reduced the accu-
mulation of A (mechanism already described in this
review). This result is especially significant since
Arrieta-Cruz reported that rat in vivo hypothalamic
A25-35 administration altered peripheral regulation
of glucose, showing that A plays an important role
in regulating glucose homeostasis [100, 101]. Cor-
respondingly, it has been reported that deposits of
A peptides can be found in different non-neuronal
tissues such as heart, liver, and pancreas as it was
reported by Troncone and colleagues [102, 103].
Zhang and colleagues demonstrated in the APP/PS1
mice model of familial AD, that A induces insulin
resistance in hepatocytes suggesting an important
role of peripheral A in modulating systemic insulin
sensitivity and glucose metabolism (A would bind
directly to the insulin receptor, affecting its signal-
ing [104, 105]. All these studies are of importance
because they reinforce the evidence that late onset
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AD should be considered as a metabolic disorder
denominated type 3 diabetes [8].
Finally, De Felice described that the neuroinflam-
matory process mediated mainly by the cytokine
TNF could be another mechanism though which
insulin signaling would be affected [5]. TNF would
bind to its receptor and induce a signaling cascade that
would activate the JNK kinases among others [13].
The JNKs, specifically the JNK1 isoform, would be a
direct inhibitor of the insulin receptor substrate 1, the
substrate of the insulin receptor, being its activation
cause for a reduction of insulin signaling and glucose
up-take, an already described symptom of possible
appearance of AD [5, 13, 96].
In the end, all the data adds up to the conclusion
that there is a real interaction between the central and
peripheral systems and that; MEM seems to be an
interesting choice to alleviate multiple biomarkers,
peripheral and central, at once.
CLINICAL TRIALS WITH MEMANTINE
It is clear that although preclinical MEM treat-
ments for AD are hopeful, the clinical results are
ineffective, none of them cure, and at most, they are
able to slow the process of cognitive loss [106]. For
example, in a clinical study (Clinical Trials identifier:
NCT00322153), 28 mg of MEM were administrated
daily orally for 24 weeks [107]. The authors used
the Severe Impairment Battery, a neuropsychological
test for severely demented patients, for the assess-
ment of cognitive function. The authors concluded
that high doses of MEM provided behavioral ben-
efits in patients with moderate to severe AD treated
in combination with an acetylcholinesterase inhibitor
(AChEIs). Howard and colleagues in a clinical study
obtained similar results using donepezil (reversible
AChEIs) in combination with MEM [108]. Thus,
the combined therapy of AChEIs with MEM has
the potential to provide benefits that either drug
alone cannot produce. Galantamine is also a possible
choice for these combined treatments since it inhibits
acetylcholinesterase activity in the synapses and can
modulate the nicotinic receptor. In a clinical study,
the combinatory regimen galantamine plus MEM was
evaluated in patients with mild to moderate probable
AD. It was a clinical multicenter, double blind, ran-
domized, parallel-group trial of 12 months of duration
(Clinical trial: NCT01921972) [109]. The objective
was to evaluate the efficacy of a combination of galan-
tamine 24 mg/day plus MEM 10 mg b.i.d. (twice a
day) with a dose titration of sixteen weeks. However,
results of this study still have not been reported. If
the expected results are positive, the drug association
should have increased synaptic activity and prevented
excitotoxicity. Another reported approach has been
the combination masitinib (tyrosine kinase inhibitor;
3–6 mg/kg/day) with MEM or/and cholinesterase
inhibitors (donepezil, rivastigmine, or galantamine)
(Clinicaltrials.gov NCT00976118) that significantly
improved the cognitive response [28]. As a result,
the first conclusion we can obtain from these results
is that more studies are necessary in order to evaluate
potential combinatory treatments in order to delay or
prevent AD, which, after all, is a multifactorial dis-
ease and might need to be treated through multiple
targets.
Annweiler and colleagues reported that the asso-
ciation of MEM plus vitamin D supplements had a
statistically and clinically significant effect on the
gain of global cognition improvement over AD symp-
toms [110, 111]. Likewise, the authors demonstrated
that the combination was more effective than tak-
ing either substance alone. Interestingly, it has been
reported that vitamin D shows neuroprotective effects
such as antioxidant action, inhibiting the synthesis of
inducible nitric oxide synthase, regulating the activity
of -glutamyl transpeptidase, increasing the synthe-
sis of nerve growth factor, showing anti-inflammatory
properties and also attenuating A1-42 accumula-
tion [111]. Therefore, the authors suggest that this
association could act by a synergic effect increas-
ing the neuroprotective action of MEM and, overall,
providing a more complete protection in patients
exposed to glutamatergic excitotoxicity. In addition,
a new recent clinical trial (NCT01409694) named
Alzheimer’s disease Input of Vitamin D with mEman-
tine Assay (AD-IDEA) is being analyzed; however,
no data have been reported from this study about the
efficacy of the association improving cognitive func-
tion. Recently the same group reported in a clinical
trial that MEM cognitive improvement depended on
the plasmatic levels of vitamin D [112].
Interestingly MEM has been evaluated in the treat-
ment of frontotemporal dementia (FTD) [113–115].
Lindquist and colleagues reported a familial case
of a patient with FTD, an adult neurodegenerative
disorder with dementia and behavioral disturbances
treated with MEM with a maintenance dosage of
10 mg twice a day. The authors suggest that, in this
specific case of a patient with pathogenic mutation
(R406W) in the microtubule associated protein tau
(MAPT) gene, MEM treatment could stabilize the
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progression of symptoms of disease [113]. However,
a multicenter, randomized, double-blind, placebo
controlled clinical trial (NCT00545974) evaluated
the efficacy of MEM in mild-to-moderate FTD and
the main conclusion of this study was that MEM treat-
ment do not ameliorate these dementia symptoms
(Table 1) [114].
Since Parkinson’s disease (PD) dementia and
dementia with Lewy bodies have some pathologi-
cal and biochemical similarities to AD, MEM have
been proposed that could provide an improvement
in these brain disorders (Table 1). Thus, the clinical
trial NCT00855686 evaluated the efficacy and safety
of MEM (20 mg per day over 6 months) in patients
with mild to moderate PD dementia or dementia with
Lewy bodies (DLB). In this study, patients were strat-
ified according to diagnosis and randomly assigned
to MEM or placebo in a double blind, parallel-group
study. The main conclusion of this study was that the
incidence of adverse events of patients treated with
MEM was low and similar to the placebo group. The
authors suggest that MEM could be a suitable strategy
for mild to moderate DLB [115].
As a note of interest, and as it can be seen in Table 1,
MEM has been evaluated as a potential therapy for
other diseases such as PD. This is because MEM is
an organic molecule of an aminoadamantane class
similar to amantadine, which produces moderate
symptomatic benefits in PD, related to tremor, tardive
dyskinesia, chorea, and dementia [116]. However,
the potential benefits of this drug are not mediated
through the potentiation of dopamine effects, so fur-
ther studies are necessary. Serafini and colleagues
evidenced that the glutamatergic system could be
involved in the pathology and treatment of depres-
sion via the modulation of post-synaptic ionotropic
receptors including the NMDAR [86]. Thus, MEM
has been reported that in association with sertraline,
a selective inhibitor of serotonin reuptake, it shows a
suitable efficacy profile in patients with major depres-
sion [88, 117–119]. Likewise, previous preclinical
reported data demonstrated that the association of
MEM with antidepressant drugs, such as fluoxetine
and venlafaxine enhances the antidepressant effect
of classical therapies. MEM associated with galan-
tamine was investigated in the treatment of cognitive
deficits in with schizophrenia [120, 121]. Others
clinical trial evaluated, a part of MEM, additional
non-pharmacological strategies for example the Envi-
ronmental Ecological Therapy in AD [122, 123].
In addition, MEM has been evaluated for cogni-
tive impairment associated with multiple sclerosis
patients, and the objective is that MEM could improve
the ability to work in severe cases of this devastating
disease [124]. The results reported in Huntington’s
disease from a randomized, placebo-controlled study,
which examines both efficacy and safety of MEM
during long-term administration (52 weeks) in non-
demented multiple sclerosis patients, were negative
for cognitive impairment improvement. Ondo and
colleagues reported that the administration of 20 mg
of MEM daily significantly improved motor symp-
toms, but failed to improve patient’s cognition [125].
Cankurtaran and colleagues reported a case study
of a 32-year-old woman with Huntington’s disease
where the drug association of risperidone with MEM
was effective in the alleviation of cognitive deficits in
this patient [126].
CONCLUSION
Although MEM shows an adequate profile in pre-
clinical AD models, clinical data have not reported
satisfactory results for curing the disease [127, 128].
Both cholinergic and glutamatergic dysfunctions are
currently key neurochemical targets for the symp-
tomatology of AD but drugs that alter these two
pathways seem to have no real applications in the
clinical cure of this disease, including MEM. Thus,
the design of combined treatments seems to be the
method to improve the current situation [129, 130].
For example, therapy with AChEI and an MEM is
an appropriate treatment strategy as the disease pro-
gresses, since there is a lack of other treatment options
in moderate to severe AD [129, 131].
The neuroprotective mechanisms of MEM in AD
against neuronal loss (apoptosis decrease and mito-
chondrial alteration) and reduction of A production
could be attributed, at least in part, to its selective
action blocking extrasynaptic NMDAR. Further-
more, in addition to extrasynaptic NMDAR blockade,
recent preclinical data provides promising results
about the brain decrease of A accumulation by
MEM in transgenic animals and age normal animals.
The new mechanism proposed by MEM would be the
reduction in A production through the regulation of
endocytosis of APP, which affects A production in
neurons. The prevention of A excessive generation
is important, because the vast majority of the preclin-
ical studies evaluated reported that MEM attenuates
or reduces soluble AO levels and fibrils and plaque
generation, which is related with the process of
memory improvement.
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Table 1
Examples of clinical research data reported with memantine
ClinicalTrials.gov
identifier
Title of the assay Objective of study Publication
NCT02234752 Galantamine and Memantine for Cognitive
Impairments in Schizophrenia
To examine the efficacy of the combination of
galantamine and MEM for the treatment of
cognitive deficits in outpatients with
schizophrenia.
[104]
NCT01461174 Effects of Donepezil and Memantine on Cognitive
Functions After a Sleep Deprivation Challenge
in Healthy Volunteers
Assess the utility of sleep deprivation as a
potential model for prediction of clinical
efficacy using a combination of cognitive
physiological endpoints.
NCT00334906 Study of Memantine in Assessment of Selected
Measures of Volumetric MRI and Cognition in
Moderate AD
Characterize the progression of disease using
volumetric MRI techniques and cognitive
outcome measures in patients with moderate
AD treated with open-label MEM.
NCT00551161 Magnetic Resonance Spectroscopy Study of
Memantine in AD
Characterize the progression of disease using
MRS, CSF biomarkers, and cognitive outcome
measures, and to determine whether changes in
cognitive function on neuropsychological
testing are correlated to changes in MR
spectroscopic and/or CSF biomarkers.
NCT01261741 Investigation of Memantine in the Treatment of
Memory, Concentration or Attention Problems
A new MEM indication in the treatment of
subjective memory, concentration, or attention
problems (subjective cognitive impairment) in
the absence of dementia.
NCT00294554 Memantine for Treatment of Cognitive
Impairment in Patients with Parkinson’s Disease
and Dementia
Evaluate the usefulness of MEM, compared to
placebo (sugar pill), for the treatment of
cognitive impairment in patients with idiopathic
Parkinson’s disease and dementia.
NCT01074619 Study on Cognitive Disorders of Multiple
Sclerosis
To determine if MEM is effective in the treatment
on cognitive disorders of Relapsing - Remitting
multiple sclerosis
NCT01876823 Memantine Plus Es-citalopram in Elderly
Depressed Patients with Cognitive Impairment
Evaluate patients with Depression-MCI with
MEM in addition to antidepressant treatment
would benefit cognitive performance and lead to
a low rate of conversion to dementia.
[102]
NCT01409694 Alzheimer’s Disease - Input of Vitamin D with
Memantine Assay (AD-IDEA)
To compare the effect after 24 weeks of the oral
intake of vitamin D3 (cholecalciferol) with the
effect of a placebo on the change of cognitive
performance in patients suffering from moderate
AD or related disorders and receiving MEM
NCT01458470 A Trial of Memantine as Symptomatic Treatment
for Early Huntington Disease (MITIGATE-HD)
To determine the effect of MEM on movement,
thinking and emotional difficulties in HD
patients.
NCT02462291 New Approach for Treatment of Behavioral
Disorders in Alzheimer’s Disease (Alzheimer’s
Behavioral and Cognitive Disorders)
The aim of this trial will be to analyze the effects
of Environmental Ecological Therapy, in people
with severe AD.
[106]
NCT00857649 Efficacy and Safety of Memantine in Moderate to
Severe Alzheimer’s Disease
The primary objective of this study is to examine
the efficacy of MEM on cognition and
behavioral symptoms in outpatients with
moderate to severe dementia of the Alzheimer’s
type.
[105]
NCT00545974 Memantine (10 mg BID) for the Frontal and
Temporal Subtypes of Frontotemporal Dementia
The primary objective of the study is to determine
whether MEM is effective in slowing the rate of
behavioral decline in frontotemporal dementia
[114]
NCT00200538 Efficacy and Tolerability of Memantine in
Frontotemporal Dementia (FTD) Patients
The purpose of this trial is to assess the efficacy
and tolerability of MEM in frontotemporal
dementia patients after a one-year treatment.
NCT00855686 Memantine Versus Placebo in Parkinson’s Disease
Dementia or Dementia with Lewy Bodies
The purpose of this study is to determine if MEM
can provide benefits on clinical symptoms in
patients with PD dementia or DLB.
[115]
(Continued)
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Table 1
(Continued)
ClinicalTrials.gov
identifier
Title of the assay Objective of study Publication
NCT00630500 Efficacy and Safety of Memantine for Parkinson’s
Disease Dementia (PDD) and Dementia with
Lewy Bodies (DLB)
A 24-week placebo-controlled parallel group
multicenter trial to study the safety and efficacy
of MEM in patients with dementia associated
with PD and DLB.
NCT00768261 Corticolimbic Degeneration and Treatment of
Dementia
The overall purpose of this research is to
determine if there is a relationship between
symptoms of Dementia of the Alzheimer’s type
and changes in the size and shape of certain
brain structures during combined Donepezil
(Aricept®) and MEM (Namenda®) treatment.
MEM, memantine; MRI, magnetic resonance imaging; AD, Alzheimer’s disease; MRS, magnetic resonance spectroscopy; CSF, cerebrospinal
fluid; PD, Parkinson’s disease; MCI, mild cognitive impairment; HD, Huntington’s disease; FTD, frontotemporal dementia; DLB, dementia
with Lewy bodies.
Likewise, MEM inhibition of tau phosphorylation
could be a process mediated also by the block-
ade of extrasynaptic NMDAR and the prevention
of intracellular calcium increase. The activation of
extrasynaptic NMDAR by glutamate and/or A leads
to an increase in intracellular Ca2+ into the postsy-
naptic cells. Intracellular Ca2+ activates calpain and
CDK5 pathway involved in tau phosphorylation. Fur-
thermore, this process can lead to excessive neuronal
oxidative stress formation that can destroy synap-
tic connections between neurons (memory loss) and
induce activation of kinases involved in tau phos-
phorylation. It has also been reported that MEM
have beneficial effects in preclinical AD models by
decreasing the activation of microglia in the rodent
brain and by increasing the production of trophic
factors.
In addition, recent reports suggest a link between
type 2 diabetes and AD, currently denominated as
type 3 diabetes where the alteration of hippocampal
insulin receptor favors cognitive loss. Interestingly,
pancreatic NMDAR are involved in insulin release,
which leads to its use in the alleviation of these
situations of insulin resistance. Furthermore, we
hypothesized that the beneficial metabolic effects
of MEM are mediated probably by an inhibition of
peripheral (pancreatic) NMDAR and the blockade of
hypothalamic A1-42 levels. Therefore, in the end it
seems that AD is a cognitive disorder associated to
metabolic alterations both in central and peripheral
areas. Considering this hypothesis, we suggest that
a combined treatment with MEM and another drug
with antidiabetic effects could be a potential strategy
to delay AD progression.
However, the lack of clinical efficacy of MEM in
AD may be due to the administration of the drug too
late when the disruption of neurons and/or synapses
is advanced and impossible to reverse. Other pos-
sible explanations might be: 1) MEM needs to be
administered with other drugs (antioxidants, anti-
inflammatory, GSK3 inhibitors, and others) in order
to potentiate its effect on the delaying and prevention
of the disease; and 2) MEM is effective in the treat-
ment of neurons but it is hard to determine whether
they remain active.
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